

Vasiliki Chounta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3860480/publications.pdf>

Version: 2024-02-01

7
papers

812
citations

1478280

6
h-index

1872570

6
g-index

7
all docs

7
docs citations

7
times ranked

454
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. <i>New England Journal of Medicine</i> , 2020, 382, 1112-1123.	13.9	266
2	Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2020, 382, 1124-1135.	13.9	232
3	Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. <i>Lancet, The</i> , 2020, 396, 1994-2005.	6.3	164
4	Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. <i>Lancet HIV,the</i> , 2021, 8, e185-e196.	2.1	80
5	Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks. <i>AIDS and Behavior</i> , 2020, 24, 3533-3544.	1.4	39
6	Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). <i>Patient</i> , 2021, 14, 849-862.	1.1	28
7	Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection. <i>BMC Infectious Diseases</i> , 2022, 22, 428.	1.3	3